PCA3 and Familial prostate cancer: TMPRSS2–ERG had an independent, additional predictive value compared to PCA3 and the ERSPC (The European Randomized Study of Screening for Prostate Cancer) risk calculator parameters with respect to the prediction of a biopsy’s Gleason score and clinical tumor stage.